ISI Group gets behind Quintiles while downgrading Pfizer's strategic partners ICON and Parexel

By Dan Stanton contact

- Last updated on GMT

ISI Group downgrades Pfizer's two strategic CROs
ISI Group downgrades Pfizer's two strategic CROs

Related tags: Pfizer

The investment bank ISI Group has selected Quintiles as its preferred CRO while concurrently downgrading Pfizer’s strategic partners Parexel and ICON.

Normally reports news rather than delve into financial speculation but with Pharma giant Pfizer hinting earlier this year it was looking at a strategic partner to accompany Parexel and ICON, we could not help question why one investment bank downgraded the two CROs to ‘neutral’ while simultaneously upgrading Quintiles.

Ross Muken from ISI who released the analyst opinions last week told there has been “no major change”​ in the industry. However, John Kreger from William Blair & Company – an investment bank which hasn’t changed its ratings for the three companies - concurred “any Pfizer changes would impact how investors think about Icon and Parexel.”

In April, Pfizer told us​ that it is “exploring the option of bringing in a third alliance partner,”​ and at the time Muken suggested Quintiles had “a great shot”​ at winning the contract.

We contacted both Pfizer and Quintiles, neither of which was able to comment on this issue.

Quintiles – Bucking the broader trend?

Muken predicted there is “still top-line momentum for the Late Phase CROs overall going forward”​ but acknowledged there are a number of risks that exist in the industry.

These include “a pick-up in Major Pharma M&A, a slowing in biotech equity fundraising and the potential for an increasingly competitive RFP environment as several large players return to the public markets - PRA​, INC​ and most notably PPD.”

However, his ”enthusiasm remains unabated for Quintiles”​ though in a note he put this down to strong book-to-bill in product development, coupled with an improving outlook for Integrated Healthcare Services (HIS), “bucking the broader trend.”

Related news

Show more

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more